Scholarlink

<p>Head and neck squamous cell carcinoma (HNSCC) accounts for sixth most common cancer worldwide. Only one third of HNSCC patients are diagnosed at an early stage. Failure in early diagnosis is one of the reasons for low survival rates in HNSCC which is mainly attributed to lack of diagnostic biomarkers The significance of p16 as a biomarker in cases of HNSCC is a subject of on-going debate and its prognostic role in HNSCC is less clear. A Prospective Cross-Sectional Study conducted in the Department of Otorhinolaryngology, Head and Neck Surgery, in collaboration with Department of Pathology, in a tertiary care hospital and teaching medical college for period of 18&#xa0;months. Of the 50 positive subjects with HNSCC, 9 patients were found to be positive for p16. Majority of the participants in our study had addiction history (94%) out of which bidi smoking (68%) was the most common. Based on site, HNSCC involving the vallecula had p16 positivity rate of 30% (<i>p</i> value &gt; 0.05), while none of the samples obtained from epiglottis, false vocal cord, buccal mucosa, floor of mouth and palate had p16 positivity. 17.8% of cases of MDSCC and 33.3% of PDSCC were p16 positive in our study. Even though p16 could be a useful biomarker for early cancer detection, however in regions still battling with addiction to tobacco-based substances, its role as a cost effective, viable diagnostic tool is still debatable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

p16 Expression in Head and Neck Squamous Cell Carcinoma

  • 期刊论文

  • 发表日期：

    2025年6月30日

查看全文
  • Malvika Aggarwal,
  • Surinder K. Singhal,
  • Nitin Gupta

摘要

Head and neck squamous cell carcinoma (HNSCC) accounts for sixth most common cancer worldwide. Only one third of HNSCC patients are diagnosed at an early stage. Failure in early diagnosis is one of the reasons for low survival rates in HNSCC which is mainly attributed to lack of diagnostic biomarkers The significance of p16 as a biomarker in cases of HNSCC is a subject of on-going debate and its prognostic role in HNSCC is less clear. A Prospective Cross-Sectional Study conducted in the Department of Otorhinolaryngology, Head and Neck Surgery, in collaboration with Department of Pathology, in a tertiary care hospital and teaching medical college for period of 18 months. Of the 50 positive subjects with HNSCC, 9 patients were found to be positive for p16. Majority of the participants in our study had addiction history (94%) out of which bidi smoking (68%) was the most common. Based on site, HNSCC involving the vallecula had p16 positivity rate of 30% (p value > 0.05), while none of the samples obtained from epiglottis, false vocal cord, buccal mucosa, floor of mouth and palate had p16 positivity. 17.8% of cases of MDSCC and 33.3% of PDSCC were p16 positive in our study. Even though p16 could be a useful biomarker for early cancer detection, however in regions still battling with addiction to tobacco-based substances, its role as a cost effective, viable diagnostic tool is still debatable.